Promoting general health during androgen deprivation therapy (ADT): A rapid 10-step review for your patients

Urologic Oncology: Seminars and Original Investigations

Volumn 23, Issue 1, 2005, Pages 56-64

  Moyad, Mark A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Androgen deprivation therapy; Androgen suppression; Dietary supplements; Lifestyle changes; Luteinizing hormone releasing hormone treatment; Prostate cancer; Side effects

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CALCIUM; CYPROTERONE ACETATE; DOCOSAHEXAENOIC ACID; ESTROGEN; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LYCOPENE; NON PRESCRIPTION DRUG; PROGESTERONE; SELENIUM; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTHRALGIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIET; ERECTILE DYSFUNCTION; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEALTH STATUS; HOT FLUSH; HUMAN; LIBIDO DISORDER; LIFESTYLE; MENTAL HEALTH; MUSCLE TONE; MYALGIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SIDE EFFECT; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; WEIGHT LIFTING; WEIGHT REDUCTION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHOLESTEROL; DIETARY SUPPLEMENTS; EXERCISE THERAPY; HEALTH PROMOTION; HEALTH STATUS; HUMANS; MALE; OSTEOPOROSIS; PATIENT EDUCATION; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 18844404133     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.03.018     Document Type: Conference Paper

References (55)

1. E.M. Messing, J. Manola, M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
2. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
3. T. Nishiyama, F. Ishizaki, T. Anraku The influence of androgen deprivation therapy on metabolism in patients with prostate cancer J Clin Endocrinol Metab 90 2005 657 660
4. M.R. Smith Osteoporosis and obesity in men receiving hormone therapy for prostate cancer J Urol 172 2004 S52 S57
5. C.S. Higano Understanding treatments for bone loss and bone metastases in patients with prostate cancer A practical review and guide for the clinician Urol Clin North Am 31 2004 331 352
6. M.A. Moyad, P.R. Carroll Lifestyle changes to prevent prostate cancer, part I Time to redirect our attention? Urol Clin North Am 31 2004 289 300
7. M.A. Moyad, P.R. Carroll Lifestyle changes to prevent prostate cancer, part II Time to redirect our attention? Urol Clin North Am 31 2004 301 311
8. K.F. Adams, C. Chen, K.M. Newton Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial Cancer Epidemiol Biomarkers Prev 13 2004 644 648
9. S. Zhan, S.C. Ho Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile Am J Clin Nutr 81 2005 397 408
10. M. Etminan, B. Takkouche, F. Caamano-Isorna The role of tomato products and lycopene in the prevention of prostate cancer A meta-analysis of observational studies Cancer Epidemiol Biomarkers Prev 13 2004 340 345
11. H.-C. Hung, K.J. Joshipura, R. Jiang Fruit and vegetable intake and risk of major chronic disease J Natl Cancer Inst 96 2004 1577 1584
12. S. Hercberg, P. Galan, P. Preziosi The SU.VI.MAX Study A randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals Arch Intern Med 164 2004 2335 2342
13. J.O. Ciocon, D.G. Ciocon, D.J. Galindo Dietary supplements in primary care Botanicals can affect surgical outcomes and follow-up Geriatrics 59 2004 20 24
14. M.K. Ang-Lee, J. Moss, C.-S. Yuan Herbal medicines and perioperative care JAMA 286 2001 208 216
15. G.K. Dy, L. Bekele, L.J. Hanson Complementary and alternative medicine use by patients enrolled onto phase I clinical trials J Clin Oncol 22 2004 4758 4763
16. A. Sparreboom, M.C. Cox, M.R. Acharya Herbal remedies in the United States Potential adverse interactions with anticancer agents J Clin Oncol 22 2004 2489 2503
17. The HOPE and HOPE-TOO Trial Investigators Effects of long-term vitamin E supplementation on cardiovascular events and cancer JAMA 293 2005 1338 1347
18. E.R. Miller III, R. Pastor-Barriuso, D. Dalal Meta-analysis High-dosage vitamin E supplementation may increase all-cause mortality Ann Intern Med 142 2005 37 46
19. M.A. Moyad Selenium and vitamin E supplements for prostate cancer Evidence or embellishment? Urology 59 suppl 4A 2002 9 19
20. M.A. Moyad The ABCs of nutrition and supplements for prostate cancer 2000 JW Edwards Publishing Ann Arbor, MI
21. M.A. Moyad Why a statin and/or another proven heart healthy agent should be utilized in the next major chemoprevention trial Part I Urol Oncol 22 2004 466 471
22. M.A. Moyad Why a statin and/or another proven heart healthy agent should be utilized in the next major chemoprevention trial Part II Urol Oncol 22 2004 472 477
23. M.A. Moyad Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease Urol Oncol 22 2004 485 489
24. R. Twombly Cancer surpasses heart disease as leading cause of death for all but the very elderly J Natl Cancer Inst 97 2005 330 331
25. R.O. Bonow, L.A. Smaha, S.C. Smith The international burden of cardiovascular disease Responding to the emerging epidemic Circulation 106 2002 1602 1605
26. C.J. Newschaffer, K. Otani, M.K. McDonald Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort J Natl Cancer Inst 92 2000 613 621
27. Katz MO, Zelefsky MJ, Marion C, et al. Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer [abstract]. Proceedings of the 45th Annual ASTRO Meeting 2003:S271 [abstract 1016].
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA 285 2001 2486 2497
29. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
30. P.M. Ridker, C.P. Cannon, D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
31. P.M. Ridker Clinical application of c-reactive protein for cardiovascular disease detection and prevention Circulation 107 2003 363 369
32. T.P. Erlinger, E.A. Platz, N. Rifai C-reactive protein and the risk of incident colorectal cancer JAMA 291 2004 585 590
33. S.R. Lentz, W.G. Haynes Homocysteine Is it a clinically important cardiovascular risk factor? Clev Clin J Med 71 2004 729 734
34. J.B. van Meurs, R.A. Dhonukshe-Rutten, S.M. Pluijm Homocysteine levels and the risk osteoporotic fracture N Engl J Med 350 2004 2033 2041
35. R.R. McLean, P.F. Jacques, J. Selhub Homocysteine as a predictive factor for hip fracture in older persons N Engl J Med 350 2004 2042 2049
36. J.A. Blumenthal, M.A. Babyak, K.A. Moore Effects on exercise training on older patients with major depression Arch Intern Med 159 1999 2349 2356
37. M. Babyak, J.A. Blumenthal, S. Herman Exercise treatment for major depression Maintenance of a therapeutic benefit at 10 months Psychosom Med 62 2000 633 638
38. R.J. Segal, R.D. Reid, K.S. Courneya Resistance training in men receiving androgen deprivation therapy for prostate cancer J Clin Oncol 21 2003 1653 1659
39. G. Cavallini, S. Caracciolo, G. Vitali Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging Urology 63 2004 641 646
40. M.A. Moyad Alternative therapies for reducing hot flashes in patients on luteinizing hormone-releasing hormone agonist treatment/orchiectomy for prostate cancer A review and the need for more research Grand Rounds in Urology 2 2000 6 10
41. M.A. Moyad Complementary/alternative therapies for reducing hot flashes in prostate cancer patients Reevaluating the existing indirect data from studies of breast cancer and postmenopausal women Urology 59 Suppl 4A 2002 20 33
42. D. Barton, C. Loprinzi, D. Wahner-Roedler Hot flashes Aetiology and management Drugs Aging 18 2001 597 606
43. A. Sikon, H.L. Thacker Treatment options for menopausal hot flashes Clev Clin J Med 71 2004 578 582
44. North American Menopause Society Treatment of menopause-associated vasomotor symptoms Position statement of The North American Menopause Society Menopause 11 2004 11 33
45. M.G. Oefelein, M.I. Resnick The impact of osteoporosis in men treated for prostate cancer Urol Clin North Am 31 2004 313 319
46. M.A. Moyad Preventing male osteoporosis Prevalence, risks, diagnosis and imaging tests Urol Clin North Am 31 2004 321 330
47. D.C. Bae, B.S. Stein The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate J Urol 172 2004 2137 2144
48. Scientific Advisory Council of the Osteoporosis Society of Canada J.P. Brown, R.G. Josse 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada CMAJ 167 suppl 10 2002 S1 S34
49. World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. WHO Technical Report Series, 843 1994 World Health Organization New York/Geneva (Switzerland)
50. M.A. Moyad Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/ orchiectomy for prostate cancer A review and assessment of the need for more research Urology 59 suppl 4A 2002 34 40
51. S.L. Ruggiero, B. Mehrotra, T.J. Rosenberg Osteonecrosis of the jaws associated with the use of bisphosphonates A review of 63 cases J Oral Maxillofac Surg 62 2004 527 534
52. R. Mascarenhas, S. Mobarhan Hypovitaminosis D-induced pain Nutr Rev 62 2004 354 359
53. P.J. Van Veldhuizen, S.A. Taylor, S. Williamson Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength J Urol 163 2000 187 190
54. H.A. Bischoff-Ferrari, B. Dawson-Hughes, W.C. Willett Effect of vitamin D on falls A meta-analysis JAMA 291 2004 1999 2006
55. J.M. Holzbeierlein, E. Castle, J.B. Thrasher Complications of androgen deprivation therapy Prevention and treatment Oncology (Huntingt) 18 2004 303 309